Erigeron Breviscapus Extract/Breviscapine 98%
Breviscapine Descriptions
1.Erigeron breviscapus Extract Breviscapine powder
2.Specification: Breviscapine 80% 95% 98%
3.Test Method: HPLC
4.Cas. No.: 116112-36-2
5.ExtractMolecular Formula: C21H18O12
6.Molecular Weight: 462.4
7.Extract Part: flower
Specifications
About Breviscapine Source
This product belongs to Erigeron reviscapus flavonsides extracted from Erigeron breviscapus (Vant.) Hand. ¨CMazz. Pharmacologydilating brain blood vessels, reducing obstruction of brain vessels, increasing blood flow in brain, improving microcirculation, and showing antiplatelet aggregation. According to the above functions, we have researched and manufactured Brevicapine tablet. It can treat paralysis resulting from cerebral vascular vascular occlusion and brain bleeding. IndicationsApplication to apoplexy, angina pectoris and coronary heart disease.
Function
1, to improve cerebral blood circulation, increase cerebral blood flow, reducing vascular resistance, increase the permeability of the blood-brain barrier, conducive to the prevention and treatment of cerebral thrombosis formation.
2, the expansion of the coronary artery and peripheral vascular, reducing myocardial oxygen consumption, to increase nutrition myocardial blood flow, improve myocardial microcirculation.
3, lower cholesterol, reduce high blood viscosity, platelet aggregation.
4, increasing the phagocytic function of the liver reticuloendothelial cells and macrophages, increased blood CAMP content, improve the immune system.
5, inhibition of intravascular coagulation, fibrinolysis promoting, reducing fibrinogen, and anti-tied thrombolysis.
Applications
healthcare product and mendcines and drugs
1, blood circulation, improve cerebral blood circulation, increase cerebral blood flow, increase myocardial ischemia, hypoxia tolerance, reduce high intraocular pressure Damage to retinal tissue.
2, for ischemic vascular disease and cerebral hemorrhage after paralysis, coronary heart disease, vascular inflammatory skin disease and rheumatism; fundus retina Static obstruction, intraocular pressure has been controlled by glaucoma and visual field damage.
